home / stock / fulc / fulc quote
Last: | $ |
---|---|
Change Percent: | -3.21% |
Open: | $16.30 |
Close: | $15.68 |
High: | $16.30 |
Low: | $15.40 |
Volume: | 41,328 |
Last Trade Date Time: | 02/12/2020 04:43:03 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $16.30 | $15.68 | $16.30 | $15.40 | 41,328 | 02-12-2020 |
$ | $16.29 | $16.20 | $17.5631 | $16.0074 | 58,493 | 02-11-2020 |
$ | $17.89 | $16.20 | $18.05 | $16.04 | 47,971 | 02-10-2020 |
$ | $16.71 | $17.97 | $18.07 | $16.71 | 50,506 | 02-07-2020 |
$ | $16.36 | $16.72 | $17.395 | $16.1773 | 58,747 | 02-06-2020 |
$ | $17.09 | $16.86 | $17.46 | $16.57 | 55,543 | 02-05-2020 |
$ | $17.29 | $17.00 | $17.565 | $16.00 | 113,076 | 02-04-2020 |
$ | $17.54 | $17.12 | $17.85 | $17.05 | 69,691 | 02-03-2020 |
$ | $17.95 | $17.24 | $18.41 | $17.10 | 61,220 | 01-31-2020 |
$ | $18.12 | $17.89 | $18.46 | $17.20 | 64,923 | 01-30-2020 |
$ | $17.58 | $18.23 | $19.10 | $17.37 | 96,862 | 01-29-2020 |
$ | $18.45 | $17.40 | $18.70 | $17.07 | 95,687 | 01-28-2020 |
$ | $17.09 | $18.13 | $19.60 | $17.00 | 108,761 | 01-27-2020 |
$ | $17.17 | $17.00 | $19.50 | $16.87 | 105,610 | 01-24-2020 |
$ | $17.73 | $16.87 | $18.28 | $16.78 | 65,997 | 01-23-2020 |
$ | $19.30 | $17.53 | $19.7378 | $17.16 | 85,350 | 01-22-2020 |
$ | $20.00 | $18.98 | $20.85 | $18.84 | 59,879 | 01-21-2020 |
$ | $18.89 | $19.89 | $21.00 | $18.495 | 150,556 | 01-20-2020 |
$ | $18.89 | $19.89 | $21.00 | $18.495 | 150,276 | 01-17-2020 |
$ | $18.3521 | $18.88 | $19.49 | $18.00 | 45,570 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...